Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
02:11p NEWLINK GENETICS : reports 2Q loss
02:11p OPPENHEIMER USA : posts 2Q profit
02:11p SEASPAN : Services Stocks Technical Commentary -- CSX Corp., Union Pacific, Greenbrier, and Seaspan
02:10p Exxon Mobil profit tumbles 59 percent in second quarter
02:10p MICROSOFT : making additional job cuts in phone business
02:10p When Big Insurance Companies Merge, Who Benefits?
02:10p AARON'S INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
02:10p SPIRIT AIRLINES, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
02:10p BARNES : Posts Lower 2nd Quarter Revenue, Profit
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
Latest news
Advertisement
Hot News 
1.94%SABMILLER : China Approves AB InBev Deal for SABMiller -- Update
1.64%AVATION : Acquires Aircraft
-9.59%Pearson Trades in Line; Books Earnings Loss
8.77%BARCLAYS : shares jump as transAtlantic refocus starts to pay off
8.18%E D F : EDF Profit Falls on Lower Electricity Prices, Deregulation
Most Read News
05:40a GOLDMAN SACHS : Oil faces big monthly loss as oversupply bites
07:40a Yen, bond yields rise as Bank of Japan action underwhelms
07/28 OAKLAND COUNTY MI : Patterson Says "No" to Regional Transit Plan that Bills Entire County but Excludes Services from 40 Oakland Communities
Most recommended articles
08:08aDJSABMILLER : China Approves AB InBev Deal for SABMiller -- Update
08:07aDJMETRO : 3Q 2016 -- Forecast
08:04a AB InBev clears China hurdle in SABMiller takeover deal
08:04aDJICICI BANK : Profit Falls by a Quarter on Non-Performing Loans
07:58a UNITED PARCEL SERVICE : UPS quarterly profit climbs on revenue growth, cost cuts